The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.
about
Development of Novel Immunotherapies for Multiple MyelomaImmune checkpoint blockade for hematologic malignancies: a reviewMolecular mechanisms by which casein glycomacropeptide maintains internal homeostasis in mice with experimental ulcerative colitis.Host-related immunodeficiency in the development of multiple myeloma.Is immunotherapy here to stay in multiple myeloma?Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionVitamin D and plasma cell dyscrasias: reviewing the significance.Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaSerum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myelomaA novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries.Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.EGCG Maintains Th1/Th2 Balance and Mitigates Ulcerative Colitis Induced by Dextran Sulfate Sodium through TLR4/MyD88/NF-κB Signaling Pathway in Rats.Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study.Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy.Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases
P2860
Q28066890-1F013923-4E27-407A-8B46-4F7322ECFF9EQ33645590-23A24C61-1FE9-4115-907C-00E9192BBC96Q33897813-EC8284CC-8FEA-4BA0-BEBA-B833F6463781Q38632529-57BB8593-232B-4C34-805B-9D166B46DBA4Q39084427-C788A06D-3EF2-4A5F-AD9D-9E50F29EB22FQ39136762-E4AECADA-60E3-40F5-B13E-318ADF37726AQ39304767-E2CF3ADD-0DD6-4ED5-91CB-E4B5954E98A0Q39901834-817CFB38-82D3-405E-929A-00403FBF1A4BQ42046550-66AE8712-BF45-4AC2-A964-B7831E2D491BQ42378344-B2C86351-2E6B-47F9-B8AA-55C2D110075DQ45761043-D3B227F8-68D3-4B82-AB6C-8B1C24373CC6Q47348957-994E7E63-D72F-49A7-9B4B-27CFAD7A4327Q47688664-6B969BCB-7FEF-4D0C-B969-1EB4AE50EE54Q48102227-F4A3F39A-9B1D-476D-848F-F897C08F4D78Q50204319-341A696E-3044-428A-9469-96C4FF57E719Q50589659-F38A70EE-1772-4CFB-9BC0-E2EDCAF66BE5Q51804210-D0187AEE-4876-42A4-81EF-C7EB02ECAD91Q52327450-231393FF-224E-4A57-A405-15D5B0BD9DD1Q57904139-A6A1AAF5-9285-40E7-83DE-59E15EBE4C55
P2860
The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The cellular immune system in ...... their uses in immunotherapies.
@ast
The cellular immune system in ...... their uses in immunotherapies.
@en
type
label
The cellular immune system in ...... their uses in immunotherapies.
@ast
The cellular immune system in ...... their uses in immunotherapies.
@en
prefLabel
The cellular immune system in ...... their uses in immunotherapies.
@ast
The cellular immune system in ...... their uses in immunotherapies.
@en
P2093
P2860
P921
P356
P1433
P1476
The cellular immune system in ...... their uses in immunotherapies.
@en
P2093
P2860
P2888
P356
10.1038/BCJ.2015.32
P5008
P577
2015-04-17T00:00:00Z